|
|
|
|
|
|
Axsome Thera (AXSM)
|
|
5.00 +0.05 (+1.01%)
|
10/20/2017 4:00pm
|
|
Open:
|
4.98
|
Pre. Close:
|
4.95
|
|
High:
|
5.10
|
Low:
|
4.90
|
|
Volume:
|
146,200
|
Market Cap:
|
118.05M
|
|
|
|
Stock Price Prediction (Update at 5:00pm est.)
|
|
If
tomorrow:
|
Open
lower
|
Open
higher
|
|
High:
|
5.18 - 5.49
|
5.49 - 5.65
|
|
Low:
|
4.71 - 4.78
|
4.78 - 4.81
|
|
Close:
|
4.9 - 5.29
|
5.29 - 5.48
|
|
|
|
|
|
|
Technical analysis (as of: 2017-10-20 4:33:39 PM)
|
|
Overall:
|
 
|
|
Stoxline posted a NEUTRAL today, upgraded from lower rating. This stock seems to stay at current move trend, but it could change at anytime. So it is not a good time to buy or sell, stay at where you are until next BUY or SELL signal.
|
|
Target:
|
Six months: 6.78 One year: 7.53
|
|
Support:
|
Support1: 4.75 Support2: 3.95
|
|
Resistance:
|
Resistance1:
5.80 Resistance2: 6.45
|
|
Pivot:
|
5.44 
|
|
Moving Averages:
|
MA(5): 5.03 MA(20): 5.46
MA(100): 5.22 MA(250): 5.19
|
|
MACD:
|
MACD(12,26):
-0.07 Signal(12,26,9): 0.02
|
|
%K %D:
|
%K(14,3): 15.69 %D(3): 14.93
|
|
RSI:
|
RSI(14): 40.46
|
|
52-Week:
|
High: 8.64
Low: 3.53 Change(%): -32.3
|
|
Average Vol(K):
|
3-Month: 11641
10-Days 4046
|
|
|
★
Strong Sell
★★
Sell ★★★
Neutral
★★★★
Buy
★★★★★
Strong Buy
|
|
|
Price, moving averages and
Bollinger Bands
|
|
Price and moving averages has closed below its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.AXSM has closed above bottom band by 21.2%. Bollinger Bands are 39.1% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
|
|
|
Headline News
|
|
Thu, 06 Jul 2017 10:52:30 GMT
Axsome Therapeutics Appoints John Golubieski as Chief Financial Officer
Thu, 25 May 2017 13:42:15 GMT
An Analysis Of Axsome Therapeutics' Upcoming Catalysts
Thu, 07 Sep 2017 11:37:30 GMT
BRIEF-Axsome Therapeutics says interim efficacy analysis of phase 3 create-1 ...
Mon, 17 Jul 2017 11:03:45 GMT
Axsome Therapeutics Initiates Phase 2/3 Trial of AXS-05 for Alzheimer's ...
Tue, 07 Mar 2017 21:33:45 GMT
Axsome Therapeutics Reports Fourth Quarter and Full Year 2016 Financial ...
|
|
|
Financial Analysis
|
|
Growth
|
|
|
Growth measures the growth of both a company's revenue
and net income. it tells investors how fast a company is growing.
|
|
Profitability
|
|
|
Profitability measures a company’s ability to
generate earnings as compared to its expenses
and other relevant costs.
|
|
Solvency
|
|
|
Solvency measures a company's ability to meet its long-term debts.
Acceptable solvency ratios will vary from industry to industry.
|
|
Efficiency
|
NA
|
|
Efficiency measures the strength of a company's return on invested capital.
It can identify business that are better managed or not.
|
|
Click here to get more fundamental analysis.
|
|
